670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660

Eitemau Tebyg

• 669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection
  gan: Jones, Courtney, et al.
  Cyhoeddwyd: (2019)
• 1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study
  gan: Mische, Sarah, et al.
  Cyhoeddwyd: (2018)
• Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile
  gan: Khanna, Sahil, et al.
  Cyhoeddwyd: (2017)
• 29. Rapid Restoration of Bile Acid Compositions After Treatment with Investigational Microbiota-based Therapeutic RBX2660 for Recurrent clostrioides Difficile Infection
  gan: Ferdyan, Nicky, et al.
  Cyhoeddwyd: (2020)
• LB5. A Long-Time Coming: Final 2-year Analysis of Efficacy, Durability, and Microbiome Changes in a Controlled Open-Label Trial of Investigational Microbiota-Based Drug RBX2660 for Recurrent Clostridioides difficile Infections
  gan: Orenstein, Robert, et al.
  Cyhoeddwyd: (2019)